Podcasts

Rewriting Faulty RNA

June 22, 2018

When Daniel de Boer’s son was diagnosed with Cystic Fibrosis, the serial entrepreneur gathered a group of biotech experts to pursue a new approach to treating rare diseases. His company ProQR is developing a platform for correcting faulty RNA that underlie specific rare diseases. We spoke to de Boer about how he came to launch ProQR, the company’s platform technology, and why the approach may be able to address a broad range of diseases.

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube